US equities collectively finished the third quarter of 2024 with record-high performance, helped by a variety of factors. Click here to read the full commentary.
Swiss medical technology company Ypsomed's contract with Novo Nordisk includes the supply of injection pens for the Danish drugmaker's next-generation experimental obesity drug CagriSema, a source ...
Our ability to interconnect data resources and repositories across services that stem from the backbone of the cloud fabric is the natural evolution of the ...
An old challenge is quickly becoming the hospital C-suite buzzword for 2025. It's "access to care." Last year we heard all about incorporating artificial intelligence smartly into healthcare. This ...